Ultragenyx Pharmaceutical Inc., of Novato, Calif., reported $16.3 million in total revenue for the fourth quarter of 2018, recognizing $11.6 million in total revenue for Crysvita (burosumab-twza), the first and only FDA-approved treatment for X-linked hypophosphatemia.